BD, Mitsubishi Gas Chemical ink pact to explore ways to advance biologic drug delivery
MGC has developed the OXYCAPT multilayer structure applied on silicon free plastic syringe barrels to provide high breakage resistance, oxygen and vapor barrier, low protein adsorption, very low extractables, high UV barrier and pH stability.
Franklin Lakes: BD (Becton, Dickinson and Company), a global medical technology company, and Mitsubishi Gas Chemical Company, Inc., a R&D-oriented chemical manufacturer based in Tokyo, Japan, have announced that they have entered into an agreement to investigate further development of OXYCAPT - an innovation from MGC that integrates the best of plastic and glass for plastic syringes.
Together, the companies will look into applying the OXYCAPT technology to the next generation of prefillable syringes (PFS) for advanced biologic pharmaceuticals.
"The biopharmaceutical industry continues to rely on PFS for the effective, reliable and consistent administration of medications," said Bruno Baney, Vice President, R&D BD Medical – Pharmaceutical Systems. "As our customers continue to grow their drug pipelines we are constantly exploring solutions to deliver newer compounds in robust, stable, and ready-to-administer formats. This agreement will further help us do so – as MGC's experience in providing technical innovation in materials will serve as a strategic complement to our legacy of supporting the latest innovations in drug delivery for our customers."
MGC has developed the OXYCAPT multilayer structure applied on silicon free plastic syringe barrels to provide high breakage resistance, oxygen and vapor barrier, low protein adsorption, very low extractables, high UV barrier and pH stability.
"Since launching OXYCAPT, more and more pharmaceutical companies have been interested in applying it to their biologics or regenerative medicines such as gene/cell therapies", said Ko Kedo, an executive officer of R&D division. "As we have looked for a strategic partner to enhance presence of OXYCAPT in the pharmaceutical industry, the partnership with BD will be an ideal solution for MGC. We believe this agreement will make it possible for customers to choose the best syringes for their drugs."
Some pharmaceutical compounds based on technologies such as mRNA, viral vectors, or innovative antibodies may face specific stability or integration with device challenges when packaged and administered in glass PFS.
Through this partnership, BD and MGC will explore practical solutions for delivering newer biologic compounds. Both companies share a commitment to advancing sustainability and reducing carbon footprint.
Read also: Reckitt Benckiser cranks up operations to put baby formula on US shelves
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.